Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Generex Biotechnology Corporation has announced that its wholly owned subsidiary, Antigen Express, has been awarded a Japanese patent strengthening its proprietary antigen presentation technology platform.
Subscribe to our email newsletter
The technology protected under the patent relates to specific methods for enhancing antigen-specific T-helper cell stimulation using small synthetic peptides. Both prophylactic and immunotherapeutic vaccine peptides are currently under development at Antigen Express.
The importance of antigen-specific T-helper stimulation in controlling the immune response has been demonstrated in many areas of immunology ranging from protection against infectious diseases to oncology to autoimmunity. Consequently, specific means for controlling T-helper cell stimulation offers the possibility of a range of therapeutics. Generex said that Antigen Express has aggressively pursued development and intellectual property coverage of its technology platforms as well as product development.